Lumen Technologies, Inc Common Stock (LUMN) had the highest return between June 1, 2024 and September 23, 2024 by a mid-cap US stock, returning 468.8%.
| ASSET | DATE | % RETURN |
|---|---|---|
Lumen Technologies, Inc Common Stock (LUMN) | 6/1/2024 - 9/23/2024 | 468.75% |
GDS (GDS) | 6/1/2024 - 9/23/2024 | 153.21% |
Clover Health Investments (CLOV) | 6/1/2024 - 9/23/2024 | 152.17% |
Terawulf (WULF) | 6/1/2024 - 9/23/2024 | 117.33% |
LandBridge Company LLC (LB) | 6/1/2024 - 9/23/2024 | 116.42% |
GPGI (GPGI) | 6/1/2024 - 9/23/2024 | 114.65% |
Aurora Innovation (AUR) | 6/1/2024 - 9/23/2024 | 112.08% |
CareDx (CDNA) | 6/1/2024 - 9/23/2024 | 111.14% |
ADMA Biologics (ADMA) | 6/1/2024 - 9/23/2024 | 107.78% |
Aveanna Healthcare (AVAH) | 6/1/2024 - 9/23/2024 | 107.63% |
Sezzle (SEZL) | 6/1/2024 - 9/23/2024 | 105.01% |
Axogen (AXGN) | 6/1/2024 - 9/23/2024 | 103.64% |
Travere Therapeutics (TVTX) | 6/1/2024 - 9/23/2024 | 95.03% |
Clear Secure (YOU) | 6/1/2024 - 9/23/2024 | 94.36% |
Skeena Resources (SKE) | 6/1/2024 - 9/23/2024 | 92.83% |
Zeta Global (ZETA) | 6/1/2024 - 9/23/2024 | 78.15% |
Viridian Therapeutics (VRDN) | 6/1/2024 - 9/23/2024 | 73.54% |
Amylyx Pharmaceuticals (AMLX) | 6/1/2024 - 9/23/2024 | 68.21% |
Compass (COMP) | 6/1/2024 - 9/23/2024 | 62.73% |
ICU Medical (ICUI) | 6/1/2024 - 9/23/2024 | 62.71% |
Cellebrite DI (CLBT) | 6/1/2024 - 9/23/2024 | 62.59% |
Perimeter Solutions (PRM) | 6/1/2024 - 9/23/2024 | 61.95% |
Protagonist Therapeutics (PTGX) | 6/1/2024 - 9/23/2024 | 61.82% |
Veracyte (VCYT) | 6/1/2024 - 9/23/2024 | 60.77% |
Denali Therapeutics (DNLI) | 6/1/2024 - 9/23/2024 | 59.92% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.